Navigation

Skiplink Navigation

Main Features

Biogen files complaint against Serono

The United States firm, Biogen, says it has filed a complaint with the Geneva prosecutor against Serono after the Swiss drugs company broke a court order banning publication of data comparing the firms' multiple sclerosis drugs.

In a briefing in London on Monday, Biogen said Serono broke the injunction by repeating claims that patients treated with its drug, Rebif, were less likely to suffer relapses than those on Avonex.

Biogen says its complaint accuses Serono of contempt of court. If found guilty, Serono's management could face imprisonment, although a fine is more likely. The maximum fine is SFr5,000 ($2,780).

Serono accuses Biogen of using the injunction to suppress the publication of a study into the rival drugs. Biogen counters that the survey's methodology was flawed.

swissinfo with agencies


Links

Neuer Inhalt

Horizontal Line


subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

×